Drug intelligence / Profile preview

Osla Redi

Development stage: Unknown
Lead developer: MerapLion
Modality: Small Molecules
Administration: Ophthalmic

Overview

**Osla Redi** is a Merap ophthalmic fixed-dose solution containing tetrahydrozoline hydrochloride and zinc sulfate. It is used for symptomatic relief of ocular irritation, including itchy, red, and blurred eyes associated with environmental irritants such as smoke, dust, swimming water, and contact-lens use. Tetrahydrozoline is a topical alpha-adrenergic vasoconstrictor that reduces conjunctival redness; zinc sulfate contributes local astringent activity. The product is supplied as eye drops and is associated with Merap's preservative-free ophthalmic technology collaboration with Lion. ([nhathuoclongchau.com.vn](https://nhathuoclongchau.com.vn/thuoc/osla-redi-15ml-15373.html))

Brand names: Osla Redi

Targets

ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on Osla Redi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osla Redi.

Explore the full profile